Angustias Y Temores De La Embarazada
Edita: Generalitat ValencianaConselleria de SanitatDirecci General de Salut PblicaElaboracin: Unidad Salud Sexual y ReproductivaC/ Rodrguez Fornos, 446010 ValenciaCoordinan: Alberto Romeu SarriCarmen Barona VilarCarmen Miralles PrezEduardo Pl ErnstElena Real RamosFelipe GarnLuis Mitjans LafontI.S.B.N.: 84-482-4051-0Depsito Legal: V-2363-2005Fecha de edicin: Junio 2005Impreso en: Kolor Litgrafos, S.L.Tel. 96 132 40 41MUJER, CULTURA Y SALUD:EL DESEO DEL HIJOLOS TEMORES DEL EMBARAZOCurso celebrado en Valenciael 10, 11 y 12 de diciembre de 20032005SUMARIOSUMARIOPresentacin ....................................................................................D. Manuel Escolano Puig, Director General de Salud Pblica.15Prlogo .............................................................................................Alberto Romeu Sarri16Prembulo ........................................................................................Elena Real Ramos17Tratamientos convencionales de la esterilidad............................Jos M Rubio Rubio19Deseo del hijo en la pareja infrtil.................................................Germn Herrero V.35De partos imposibles en las miscelneas del siglo XVI .............Lina Rodriguez Cacho45La figura de la madre en la poesa popular..................................Csar Real Ramos69Tratamientos paramdicos de la esterilidad ................................Antonio Gonzlez Santana93Imaginario de la maternidad...........................................................Rafael Garca Mahques103Reflexiones en torno a la concepcin y a la aconcepcin en laadolescencia ....................................................................................Luis Mitjans Lafont, Pepa Gonzlez Sala133Sentimiento de fracaso y depresin .............................. Continue reading >>
Lantus, Toujeo (insulin Glargine) Dosing, Indications, Interactions, Adverse Effects, And More
100 units/mL (Lantus SoloSTAR; Basaglar KwikPen; 3 mL disposable prefilled pens) 300 units/mL (Toujeo; 1.5 mL SoloStar disposable prefilled pen) 300 units/mL (Toujeo Max; 3 mL SoloStar disposable prefilled pen) Note: Recent studies have suggested that glargine-300 extends blood glucose control well beyond 24 hr Long-acting basal insulin indicated to improve glycemic control in adults with type 1 diabetes mellitus Start ~1/3 of total daily insulin dose; use remaining 2/3 of daily insulin dose on short-acting, premeal insulin Usual initial dose range: 0.2-0.4 units/kg; optimal glucose lowering effect may take 5 days to fully manifest and the first insulin glargine dose may be insufficient to cover metabolic needs in the first 24 hr of use Titrate insulin glargine per instructions, and adjust coadministered glucose-lowering therapies per standard of care See Dosing Considerations and Administration Long-acting basal insulin indicated to improve glycemic control in adults with type 2 diabetes mellitus Start 0.2 units/kg qDay; if necessary, adjust dosage of other antidiabetic drugs when starting insulin glargine to minimize the risk of hypoglycemia See Dosing Considerations and Administration Dose must be individualized based on clinical response; blood glucose monitoring is essential in all patients receiving insulin therapy Patients adjusting the amount or timing of dosage should do so only under medical supervision with appropriate glucose monitoring Titrate Toujeo dose no more frequently than every 3-4 days Use with caution in patients with visual impairment who may rely on audible clicks to dial their dose If changing from a treatment regimen with an intermediate- or long-acting insulin to a regimen with insulin glargine, the amount and timing of shorter-acting insulin Continue reading >>
(insulin Glargine Injection) 300 Units/ml
If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610. The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment. Continue reading >>
Toujeo Insulin: The Major Problem I Had With This Insulin
I was in love with Toujeo insulin when I first started taking it. It addressed my two major complaints with Lantus insulin: the 5-hour peak after injecting it (which means my blood sugar would plummet between 3 a.m. and 5 a.m. down to 40 mg/dL) and the burning pain it caused in every injection because its very acidic. These are two things I can certainly work around, by going to bed with my blood sugar 130 mg/dL instead of 80 mg/dL (not ideal!) and by just dealing with the 10 seconds on burning pain…but what would be even better is an insulin that didn’t burn and didn’t peak 5 hours after injecting it. At first, it seemed like Toujeo was going to be that solution. I started taking it near the end of September. I was so in love with this insulin that I wrote this article, Toujeo: 5 Reasons Why I Love It! I can’t recall exactly when things started to go haywire, but it was after at least two or three weeks of taking Toujeo. The first few weeks were wonderful. Smooth and steady blood sugars. No burning pain. No lows at 5 a.m. Wonderful. The recommended conversion of your Lantus dose to your Toujeo dose seemed to be perfect for me: a 20% increase in your Lantus dose should be your Toujeo dose, because even though Toujeo is more concentrated (a u300 insulin), you actually need more, not less. Then Things Got Messy… And then things got messy. And gradually, over the course of two months, they continued to get even messier. Unfortunately, I wasn’t able to wear my DexCom CGM during this span of time because my receiver died in early November and I’ve been going through the painfully slow process of getting my new one because of insurance nonsense. Regardless, it would’ve been extremely helpful to have my CGM on during this span of time! It’s Gotta Be My Fault� Continue reading >>
- Mice Have Had Their Diabetes Reversed After Receiving Pancreatic Tissue Grown in Rats
- R.I.P. Dr. Sebi: Man Who Had Remedies To Cure AIDS, Cancer, Diabetes & More Passes Away At Age 82! (Interview Speaking On His Supreme Court Trial)
- I Had Lost All Hopes, Believed That I Would Have To Live With Diabetes All My Life. Now I’m An Ex Diabetic Thanks To This
6-5-15 Beacon_beacon 10
1 Free A Paper Designed With Readers in Mind June 5 - 18, 2015 Whitewater was once the Mecca of Modern Spiritualism In the 1850s, a wave of spiritualism for a telephone company facility. swept the nation. The press reported According to Whitewater historian spirits knocking on tables, children Carol Cartwright, Once the school speaking in tongues, psychic healers vacated the building, the rumors and sto- who cured by laying on hands, and medi- ries of what took place there intensified. ums who spoke with the dead. The building was used for other purpos- Whitewater, Lake Mills, and es, including several years as College Waterloo were local hotbeds of the House, a girls dormitory for the State movement, and Milton farmer Morris Teachers College. Pratt (1820-1902) could usually be found It might have been at that time that at spiritualist meetings. the real story of the Morris Pratt In 1851, Pratt visited the Lake Mills Institute became mixed with the imagi- Spiritualist Center. He was a well edu- nations of college students and the more cated man, and following his visit to outlandish rumors began. And, it is pri- Lake Mills, he embraced and advocated marily the college students who have spiritualism. In fact, he was known to passed along and embellished the stories frequently argue with ministers who con- of Whitewaters supposed occult prac- demned spiritualism, to the point of tices, ghosts, and witches. being evicted from churches on several The school still exists today, relocat- occasions. Whitewaters Morris Pratt Institute was built in 1889 and enrolled its first stu- ed to Milwaukee, and one can enroll by Not being particularly welcomed in dents in 1902 to study spiritualism. The school is now located in Milwaukee. mail to study clairvoyance, telepathy, area churc Continue reading >>
Fda Approves New Long-acting Insulin
On February 25, 2015, the U.S. Food and Drug Administration (FDA) approved the once-daily, long-acting insulin Toujeo (generic name insulin glargine 300 U/ml) for controlling blood glucose in adults with Type 1 and Type 2 diabetes. The medicine, which is manufactured by pharmaceutical company Sanofi, joins basal insulins Lantus (insulin glargine 100 U/ml) and Levemir (insulin detemir) on the U.S. market. Basal, or background insulin, is typically taken once daily to cover the liver’s secretion of glucose into the bloodstream. Toujeo has the same active ingredient as Lantus, but it is three times the concentration and is designed to release more gradually. In a series of international studies involving more than 3,500 adults with Type 1 and Type 2 diabetes, Toujeo produced similar blood glucose control to Lantus, but with lower rates of hypoglycemia (low blood glucose). This medicine should not be used in people under 18 or to treat diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body). The most common side effects of Toujeo (apart from hypoglycemia) are nasopharyngitis (inflammation of the nose and pharynx) and upper respiratory tract infection. Toujeo is expected to debut in the United States in April 2015 and will be available in the Toujeo SoloSTAR, a prefilled, disposable pen containing 450 units of the medicine. Information on pricing is not currently available. For more information about Toujeo, see the press release on Sanofi’s website or visit the official Toujeo website. And to learn more about using long-acting insulin, see “Getting Down to Basals,” by 2014 Diabetes Educator of the Year Gary Scheiner. Continue reading >>
Insulin Glargine Injection For Subcutaneous Use
Toujeo (insulin glargine) Injection is along-acting insulin indicated to improve glycemic control in adults with diabetes mellitus. Common side effects of Toujeo include: cold symptoms upper respiratory tract infection allergic reactions injection site reactions itching rash swelling of extremities, and weight gain The recommended starting dose of Toujeo in insulin na�ve patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be given as a short-acting insulin and divided between each daily meal. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin na�ve patients with type 1 diabetes. The recommended starting dose of Toujeo in insulin na�ve patients with type 2 diabetes is 0.2 units per kilogram of body weight once daily. Toujeo may interact with other antidiabetic drugs, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blocking agents (ARBs), disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors (MAOIs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics, antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isonazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic drugs, thyroid hormones, alcohol, beta-blockers, clonidine, lithium salts, clonidine, guanethidine, and reserpine. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Toujeo. Insulin requirements may change during pregnancy. It is unknown if Toujeo passes into breast m Continue reading >>
(insulin Glargine Injection) 300 Units/ml
Do not take Toujeo® if you have low blood sugar or if you are allergic to insulin or any of the ingredients in Toujeo®. Do NOT reuse needles or share insulin pens even if the needle has been changed. Before starting Toujeo®, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed. Continue reading >>
